Changes in lymphocyte phenotype and increased skin allograft survival after FTY720+FK506 therapy

Revista Brasileira de Hematologia e Hemoterapia

Volumn 30, Issue 3, 2008, Pages 181-187

  Lopes, Camila T ^a   Silva, Léa B L ^a   Cury, Patricia M ^a   Burdmann, Emmanuel A ^a   Bueno, Valquiria ^b,c  

^a FACULDADE DE MEDICINA DE SÃO JOSÉ DO RIO PRETO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Flow cytometry; Immunosuppression; Mice; Rejection; Skin allotransplantation

Indexed keywords

EID: 54949122535     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842008000300005     Document Type: Article

References (33)

1. Maki T, Gottschalk R, Ogawa N, Monaco AP. Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation. 2005;79(9):1051-5.
2. Azuma H, Takahara S, Horie S, Muto S, Otsuki Y, Katsuoka Y. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 2003;169(6):2372-7.
3. Schmid G., Guba M, Papyan A, Ischenko I, Brückel M. FTY720 inhibits tumor growth and angiogenesis. Transplant Proc. 2005;37(1):110-1
4. Ueda H, Takahara S, Itoh S, Nomi H, Shibahara N, Katsuoka Y. Preoperative administration of FTY720 prolonged renal allograft survival. Transpl Immunol. 2005;14(1):1-8.
5. Oliveira CM, Borra RC, Franco M, Schor N, Pestana JO, Bueno V. FTY720 impairs necrosis development after ischemia-reperfusion injury. Transplant Proc. 2004;36(4):854-6.
6. Suleiman M, Cury PM, Pestana JO, Burdmann EA, Bueno V. FTY720 prevents renal T-cell infiltration after ischemia/reperfusion injury. Transplant Proc. 2005;37(1):373-4.
7. Chiba K, Yanagawa Y, Nasubuchi Y, Kataoka H, Kawaguchi T, Ohtsuki M. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998;160(10):5037-44.
8. Goetzl EJ, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest. 2004;114(11):1531-7.
9. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res. 2003;47(5):401-7.
10. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem. 2004;279(20):20555-8.
11. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem. 2004;92(5):882-99
12. Olivera A, Rivera J. Sphingolipids and the balancing of immune cell function: lessons from the mast cell. J Immunol. 2005;174(3):1153-8
13. Graeler M, Goetzl EJ. Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J. 2002;16(14):1874-8.
14. Wang W, Graeler MH, Goetzl EJ. Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4+ regulatory T Cells. FASEB J. 2004;18(9):1043-5.
15. Goetzl EJ, Kong Y, Mei B. Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax. J Immunol. 1999;162(4):2049-56.
16. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science. 2002;296(5566):346-9.
17. Sugito K, Koshinaga T, Inoue M, Ikeda T, Hagiwara N, Fukuzawa M. The effect of a novel immunosuppressant, FTY720, in mice without secondary lymphoid organs. Surg Today. 2005;35(8):662-7
18. Morris MA, Gibb DR, Picard F. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720. Eur J Immunol. 2005;35(12):3570-80.
19. Yagi H, Kamba R, Chiba K, Soga H, Yaguchi K. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol. 2000;30(5):1435-44.
20. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA. 2003;100(19):10907-12.
21. Xie JH, Nomura N, Koprak SL, Quackenbush EJ, Forrest MJ, Rosen H. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol. 2003;170(7):3662-70.
22. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004;18(3):551-3
23. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-60.
24. Silva FR, Silva LB, Cury PM, Burdmann EA, Bueno V. FTY720 in combination with cyclosporine - an analysis of skin allograft survival and renal function. Int Immunopharmacol. 2006;6(13-14):1911-8.
25. Gillot BJ, Jones ND, Hara M, Wood KJ. Visualization of the in vivo generation of donor antigen-specific effector CD8+ T cells during mouse cardiac allograft rejection: in vivo effector CD8+ T cell generation during allograft rejection. Transplantation. 2000; 69(4):639-48.
26. Hanshaw RG, Smith BD. New reagents for phosphatidylserine recognition and detection of apoptosis. Bioorg Med Chem. 2005; 13(17):5035-42.
27. Gallo AP, Silva LB, Franco M, Burdmann EA, Bueno V. Tacrolimus in combination with FTY720 - an analysis of renal and blood parameters. Int Immunopharmacol. 2006;6(13-14):1919-24.
28. Henning G, Ohl L, Junt T, Reiterer P, Brinkmann V, Nakano H et al. CC chemokine receptor 7-dependent and -independent pathways for lymphocyte homing: modulation by FTY720. J Exp Med. 2001;194(12):1875-81.
29. Hwang MW, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation. 1999;100(12):1322-9.
30. Grusby MJ, Auchincloss H, Lee R, Johnson RS, Spencer JP, Zulstra M et al. Mice lacking major histocompatibility complex class I and class II molecules. Proc Natl Acad Sci USA. 1993;90(9):3913-7.
31. Yanagawa Y, Hoshino Y, Chiba K. The significance of timing of FTY720 administration on the immunosuppressive effect to prolong rat skin allograft survival. Int J Immunopharmacol. 2000; 22(8):597-602.
32. Halamay KE, Kirkman RL, Sun L, Yamada A, Fragoso RC, Shimizu K et al. CD8 T cells are sufficient to mediate allorecognition and allograft rejection. Cell Immunol. 2002;216(1-2):6-14.
33. Wang MH, Milekhin V, Zhang H, Huang HZ. FTY720, a new immunosuppressant, as rescue therapy in mouse cardiac transplantation. Acta Pharmacol Sin. 2003;24(9):847-52.